GTG Stock Overview
A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.039 |
| 52 Week High | AU$0.30 |
| 52 Week Low | AU$0.036 |
| Beta | 0.48 |
| 11 Month Change | 0% |
| 3 Month Change | -13.33% |
| 1 Year Change | -80.50% |
| 33 Year Change | -93.50% |
| 5 Year Change | -91.33% |
| Change since IPO | -99.83% |
Recent News & Updates
Shareholder Returns
| GTG | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 0% | -6.0% | 1.5% |
| 1Y | -80.5% | 11.8% | 17.2% |
Return vs Industry: GTG underperformed the Australian Life Sciences industry which returned 11.8% over the past year.
Return vs Market: GTG underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| GTG volatility | |
|---|---|
| GTG Average Weekly Movement | 11.6% |
| Life Sciences Industry Average Movement | 11.2% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: GTG has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: GTG's weekly volatility has decreased from 18% to 12% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 55 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| GTG fundamental statistics | |
|---|---|
| Market cap | AU$5.67m |
| Earnings (TTM) | -AU$12.02m |
| Revenue (TTM) | AU$9.67m |
0.6x
P/S Ratio-0.5x
P/E RatioIs GTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTG income statement (TTM) | |
|---|---|
| Revenue | AU$9.67m |
| Cost of Revenue | AU$3.76m |
| Gross Profit | AU$5.91m |
| Other Expenses | AU$17.93m |
| Earnings | -AU$12.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 61.12% |
| Net Profit Margin | -124.24% |
| Debt/Equity Ratio | 35.2% |
How did GTG perform over the long term?
See historical performance and comparison